Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nadolol · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nadolol (1 x 80 mg) Tablets (Invamed, Inc) |
| 2 | ACTIVE_COMPARATOR | Corgard (1 x 80 mg) Tablets (Bristol Laboratories) |
| Name | Type | Description |
|---|---|---|
| Nadolol (1 x 80 mg) Tablets (Invamed, Inc) | DRUG | - |
| Corgard (1 x 80 mg) Tablets (Bristol Laboratories) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Nadolol is a small molecule drug studied for high blood pressure, with trial conditions also listing migraine headaches and chest pain. It is being developed by Novartis AG under ticker NVS and remains in Phase 1 clinical development, so it is investigational and not approved for these uses.
Nadolol targets ADRB1 and ADRB2, the beta-1 and beta-2 adrenergic receptors. It acts as an antagonist at these receptors, meaning it blocks their activity. This receptor-blocking mechanism underlies its study in cardiovascular and neurological conditions such as high blood pressure.
Novartis AG, which trades under the ticker NVS, is the developer of Nadolol. The drug is also known as Nadolol (1 x 80 mg) Tablets (Invamed, Inc), reflecting the tablet formulation used in its clinical study.
Nadolol is in Phase 1 clinical development. Its single recorded trial is a completed Phase 1 bioavailability study, and no active trials are ongoing. Because it is still investigational, Nadolol has not been established as an approved treatment for high blood pressure or any other indication.
Nadolol has been studied in one completed Phase 1 trial, NCT00960245, titled Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions. The trial enrolled 34 healthy male volunteers aged 18 years and older and used an active-controlled, randomized design.